Investors
Investor Center
Aton (LSE: ALTAO) is a lifesciences group invested in the future of medicine, to improve patient care and treatment safety. Aton guides and grows a portfolio of leading-edge companies, each deploying a specialism, working in synergy to advance tomorrow’s therapies.
COMPANY INFORMATION
Headquarters:
850 boulevard Sébastien Brant, 67400 Illkirch Graffenstaden
Status:
Limited company with Board of Directors
Share capital:
10.077.051,35 euros. (as of May 12, 2026)
Total number of shares:
1.007.705.135
Qualification (FCPI):
2014-2017
Auditor:
AVVENS
S3C GESTION
IPO:
December 17, 2007
Market:
Euronext Growth
Ticker code:
ALTAO
ISIN code:
FR0004153930
Cotation type:
continuous
Listing sponsor:
Atout Capital
Liquidity agreement:
none
OUR PLATFORMS
Game-changing life science platforms
Our platforms are driving a fundamental shift to provide opportunities for more personalization and precision products and services. Diverse platforms, each with unique world-leading technologies and a team of experts united by one desire, to advance and accelerate medical discoveries for the good of patients, medicine, and society. Aton’s platforms bring significant expertise to guide and support life science businesses in achieving their goals with greater efficiency.
Preclinical & Clinical Services
Preclinical & Clinical Services
We accelerate and secure the entire drug development process with a patient-centred approach, optimizing our customers' time and resources so...
Learn more
Monoclonal Antibodies Production
Monoclonal Antibodies Production
Bcell Design is a leading provider of leading-edge monoclonal antibodies with human Fc for companies specializing in in vitro diagnostic...
Learn more
Laboratory Equipment Production
Laboratory Equipment Production
Its accuracy and sensitivity surpass traditional methods, facilitating real-time analysis and personalized medicine. Unravel the complexities of molecular behaviors and...
Learn more
Human Tissue Provision
Human Tissue Provision
We ensure that all clinical tissues are procured through rigorous ethical guidelines, with informed consent obtained from donors.
Learn more
Shareholder Webinar — May 2026
Watch our May 2026 shareholder webinar: financial restructuring update, overview of our three subsidiaries (Inoviem Scientific, PIMS Technology, B Cell Design) and key milestones ahead for 2026.